ASH 2022 | Camidanlumab tesirine in patients with triple-class refractory Hodgkin lymphoma

Camidanlumab tesirine is an antibody-drug conjugated targeting CD25. That means that this agent targets both regulatory T cells but also Hodgkin lymphoma cells. Camidanlumab tesirine has been extensively investigated in the relapsed/refractory Hodgkin lymphoma through a Phase I study involving more than 100 patients and a Phase II study involving even more than 100 patients. Camidanlumab in the setting of relapsed/refractory patients has been particularly investigated in patients that had failed autologous stem cell transplantation and failed brentuximab vedotin and have failed also anti PD1 monoclonal antibodies. So the setting is the clinical setting where camidanlumab has been investigated is one of the worst, because these patients have failed three main drugs that are available with curative intents.

Triple-negative Hodgkin lymphoma patients represent today the real unmet medical need in Hodgkin lymphoma patients. Because these patients had failed three curative options and essentially they have nothing else that can be used to allow patients to achieve a complete remission and eventually to be cured. However, despite being tested in a very difficult clinical setting, camidanlumab tesirine is associated with a very high percentage of response, both complete response and partial response. This finding opens a new avenue because patients triple refractory who achieve a complete remission status or partial remission status as acceptable to be addressed to an allogeneic stem cell transplantation that’s yet can represent a curative approach for these patients.